Acute Respiratory Distress Syndrome and Posterior Reversible Encephalopathy Syndrome following Rituximab Therapy.
The anti-CD20 monoclonal antibody rituximab is associated with rare but significant adverse events, notably posterior reversible encephalopathy syndrome (PRES) and acute respiratory distress syndrome (ARDS). We report a case of concomitant ARDS and PRES developing after rituximab therapy for treatment of cryoglobulinaemic vasculitis. There are 7 reported cases of PRES complicating rituximab use. PRES onset varied from immediate to 21 days after administration. All patients recovered completely, and rituximab was reintroduced in half of the cases. The occurrence of ARDS in association with rituximab is rarer. Only 3 confirmed cases exist, and ARDS may occur as a delayed reaction.
Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
Katrina E
KE
Wardrope
Scottish National Blood Transfusion Service, Edinburgh, UK.
Lynn
L
Manson
Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
Wendy
W
Metcalfe
Department of Renal Medicine, Royal Infirmary of Edinburgh, Edinburgh, UK.
Eoin D O
ED
Sullivan
Acute respiratory distress syndrome; Cryoglobulinaemia; Posterior reversible encephalopathy syndrome; Rituximab